446263-95-2 Usage
General Description
6-amino-3-Pyridinepropanoic acid methyl ester is a chemical compound with the molecular formula C8H11N3O2. It is an ester derivative of 6-amino-3-pyridinepropanoic acid, which is an important intermediate in the synthesis of pharmaceutical drugs and agrochemicals. 6-amino-3-Pyridinepropanoic acid methyl ester is commonly used as a precursor in the production of various medications, particularly those used in the treatment of central nervous system disorders. It is also utilized in the synthesis of certain pesticides and insecticides. Additionally, 6-amino-3-pyridinepropanoic acid methyl ester has potential applications in organic synthesis and medicinal chemistry due to its unique structural properties and reactivity. Overall, this compound plays a key role in the development and manufacture of a wide range of important products in the pharmaceutical and agricultural industries.
Check Digit Verification of cas no
The CAS Registry Mumber 446263-95-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,6,2,6 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 446263-95:
(8*4)+(7*4)+(6*6)+(5*2)+(4*6)+(3*3)+(2*9)+(1*5)=162
162 % 10 = 2
So 446263-95-2 is a valid CAS Registry Number.
446263-95-2Relevant articles and documents
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
Miller, William H.,Seefeld, Mark A.,Newlander, Kenneth A.,Uzinskas, Irene N.,Burgess, Walter J.,Heerding, Dirk A.,Yuan, Catherine C. K.,Head, Martha S.,Payne, David J.,Rittenhouse, Stephen F.,Moore, Terrance D.,Pearson, Stewart C.,Berry, Valerie,DeWolf Jr., Walter E.,Keller, Paul M.,Polizzi, Brian J.,Qiu, Xiayang,Janson, Cheryl A.,Huffman, William F.
, p. 3246 - 3256 (2007/10/03)
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began w
